idiopathic pulmonary fibrosis

Improved quality of life, reduced quantitative lung fibrosis in a trial of inhaled pirfenidone for idiopathic pulmonary fibrosis

Kim GHJ, Woodhead FA, Nair D, Bao H, Lazarus HM, Conoscenti CS, Goldin JG. Improved quality of life, reduced quantitative lung fibrosis in a trial[...]

By afschroeder • March 23, 2026

Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative – Group 3 Pulmonary Hypertension

Piccari L, Allwood B, Antoniou K, Chung JH, Hassoun PM, Nikkho SM, Saggar R, Shlobin OA, Vitulo P, Nathan SD, Wort SJ. Pathogenesis, clinical features,[...]

By sjmartinez • April 8, 2023